• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
The Genome
CMECNE

ACOG Addresses Preimplantation Genetic Testing

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss the different types of preimplantation genetic testing
2. Describe the limitations of preimplantation genetic testing

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 12/01/2022 through 12/01/2024, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the test and evaluation. Upon registering and successfully completing the test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

Preimplantation genetic testing (PGT) is becoming more common within IVF programs. It is a way to perform genetic testing prior to embryo transfer. The ACOG document reviews the current nomenclature and requirements for confirmatory testing later in pregnancy.

WHAT IS IT?

  • Most often, a biopsy is performed at the blastocyst stage, allowing 5 to 10 cells to be removed for further genetic testing. The goal is to identify unaffected embryos for transfer. There are different types of testing, depending on genetic disorder that is being assessed.

PGT-M: PGT for Monogenic Disorders

  • This category covers single gene disorders | Mutations are at the level of individual genes
    • The embryo is tested for pathogenic variants
  • PGT-M is an option for
    • Autosomal recessive or dominant single-gene disorders (e.g., cystic fibrosis): PGT-M is offered when a pregnancy has been identified to be at high risk through preconception carrier screening testing (either routine or known disorder within the family)
    • Heritable cancer syndromes: Patients may opt for PGT-M if a high risk pathogenic variant has been identified in genes (e.g., BRCA1/2) where mutations are known to predispose to cancers
    • HLA typing: PGT-M has been used to identify the HLA status of a fetus with the potential for cord blood or bone marrow matching for sick family members
  • Caution
    • Current PGT-M techniques provide accurate results, but false positives and negatives may occur
    • Usually only specific genes and relevant variants are targeted
  • Confirmatory CVS or amniocentesis should be offered

PGT-SR: PGT for for Structural Rearrangements

  • This category covers structural rearrangements, which refer to genomic alterations at the chromosomal level
    • Examples of structural rearrangements: Translocations | Inversions | Deletions | Insertions
    • While the individual parent usually has a normal amount of DNA (e.g., a ‘balanced’ rearrangement), the fetus is at risk for gain or loss of chromosomal material that may occur during meiosis
    • Genetic counseling prior to pregnancy is recommended for individuals with structural rearrangements and should include a discussion regarding the option of PGT-SR
  • Caution
    • Current methods identify overall amount of DNA
    • Some parental translocations may result in both chromosome copies being inherited from the same parent, leading to ‘imprinting’ errors
    • PGT-SR tests for overall amount of DNA, not parental source and, therefore, cannot currently exclude the possibility of disorders due to imprinting

PGT-A: PGT for Aneuploidy

  • PGT-A screens for whole whole chromosome abnormalities such as trisomy 21 (Down syndrome)
    • Current technologies can assess all chromosomes
  • One of the goals of PGT-A has been to enhance the quality of embryos for transfer by sorting out those with aneuploidy
  • Caution
    • Data has been inconsistent regarding clinical utility
    • ASRM does not currently recommend routine use of PGT-A to all infertile women

KEY POINTS:

Confirmatory Genetic Testing During Pregnancy

  • Confirmatory testing is recommended for all women undergoing PGT
    • CVS or amniocentesis may be offered
  • ACOG states

Traditional diagnostic testing or screening for aneuploidy should be offered to all patients who have had preimplantation genetic testing-aneuploidy, in accordance with recommendations for all pregnant patients

  • Counseling should include the following key points
    • PGT currently cannot detect all microdeletions or microduplications, or new pathogenic variants
    • Children may still be born with birth defects despite normal PGT report either from genetic changes not covered by PGT or unrelated to single-gene or chromosomal abnormalities
  • If a patient declines the option of confirmatory testing
    • Patients may opt for aneuploidy screening
    • Inform patients that screening is not the same as diagnostic testing and false negatives and false positives may occur

PGT-A and Mosaicism

  • Mosaicism is a recognized limitation of PGT-A
    • A single embryo may have more than one cell line (e.g., one cell has 3 copied of chromosome 21 (i.e., Down syndrome), while another cell has a normal chromosomal complement
    • May occur in up to 20% of PGT-A
    • Some embryos with mosaicism may continue to delivery and result in normal infants at term, depending on the chromosomes that are involved | Pregnancy rates may be decreased
    • “Referral to a specialist with genetic training and expertise should be considered”
    • Patient should be “strongly encouraged” to opt for confirmatory testing during pregnancy

Learn More – Primary Sources:

ACOG Committee Opinion 799: Preimplantation Genetic Testing

ASRM: The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion

Take a post-test and get CME credits

TAKE THE POST TEST

Get Guideline Notifications direct to your phone with ObGFirst™

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All The Genome Posts
Next >

Related ObG Topics:

Does Embryo Biopsy during IVF Lead to More Monozygotic Twins?
What is the Best Technique to Use for Preimplantation Screening?
Genetic Carrier Screening in Ashkenazi Jewish Patients
ASRM guidance: ART and recommended number of embryos to transfer

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site